Phase 1 Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 75 years old at the time of signing the consent form
- People who have been diagnosed with adult-onset rheumatoid arthritis (RA), based on a specific set of recognised classification guidelines from 2010
- People whose RA is considered moderately to severely active
- People whose blood tests show positive results for certain markers associated with RA (called RF and/or ACPA) at the screening stage
- People who have not had enough benefit from, or could not tolerate, certain types of RA medications known as tsDMARDs and/or bDMARDs (confirm with trial site for specific medication history requirements)
Who may not be able to join:
- People whose blood test results fall outside acceptable ranges at the screening stage
- People who have an active infection at the time of screening
- People who have received a live vaccine within 4 weeks before the screening visit
- People who have another autoimmune disease alongside their RA
- People with a history of a serious brain condition called progressive multifocal leukoencephalopathy
- People with a history of a primary immune system disorder or an inherited deficiency affecting the complement system (a part of the immune system)
- People who have a condition affecting the central nervous system (the brain and spinal cord)
- People who have one or more other significant medical conditions, as judged by the investigating doctor
- People who have been diagnosed with or treated for a malignant disease (such as cancer) within the past 5 years
- People with serious mental illness, alcohol or drug abuse, dementia, or any other condition that the trial site determines would affect their ability to receive treatment or to understand and consent to participation
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Qiubai Li, Professor, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phone: 85726808
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and severity of treatment-emergent adverse events through end of study; Changes from baseline in vital signs through end of study: body temperature; Changes from baseline in vital signs through end of study: heart rate; Changes from baseline in vital signs through end of study: respiratory rate; Changes from baseline in vital signs through end of study: blood pressure; Changes from baseline in vital signs through end of study: pulse oximetry; Changes from baseline in ECG parameters through end of study: PR interval; Changes from baseline in ECG parameters through end of study: QRS in...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.